National Institute of Dental and Craniofacial Research; Notice of Meeting, 80555-80556 [2022-28448]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel; RFP
Review: National NeuroHIV Tissue
Consortium (NNTC) Clinical Sites and Data
Coordination Centers.
Date: January 24, 2023.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Nicholas Gaiano, Ph.D.,
Review Branch Chief, Division of Extramural
Activities, National Institute of Mental
Health, National Institutes of Health,
Neuroscience Center/Room 6150/MSC 9606,
6001 Executive Boulevard, Bethesda, MD
20892–9606, 301–443–2742, nick.gaiano@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: December 27, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–28446 Filed 12–29–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
khammond on DSKJM1Z7X2PROD with NOTICES
National Institute of Mental Health;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Initial Review Group;
Effectiveness of Mental Health Interventions
Study Section.
Date: February 3, 2023.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Marcy Ellen Burstein,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
Neuroscience Center, 6001 Executive Blvd.,
Room 6143, MSC 9606, Bethesda, MD 20892–
9606, 301–443–9699, bursteinme@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: December 27, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–28445 Filed 12–29–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Human Genome Research.
The meeting will be open to the
public as indicated below. Individuals
who need special assistance, such as
sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting. The meeting
will be videocast and can be accessed
from https://www.genome.gov/aboutnhgri/Institute-Advisors/NationalAdvisory-Council-for-Human-GenomeResearch.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Human Genome Research.
Date: February 13–14, 2023.
Closed: February 13, 2023, 10:00 a.m. to
11:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
80555
Rockledge Drive, Suite 1100, Bethesda, MD
20892 (Virtual Meeting).
Open: February 13, 2023, 11:30 a.m. to 6:00
p.m.
Agenda: Report of Institute Director and
Institute Staff.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 1100, Bethesda, MD
20817 (Virtual Meeting).
Closed: February 14, 2023, 10:00 a.m. to
5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 1100, Bethesda, MD
20817 (Virtual Meeting).
Contact Person: Rudy O. Pozzatti, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, 6700 Rockledge Drive, Suite 1100,
Rockville, MD 20852, (301) 402–0838,
pozzattr@mail.nih.gov.
Any interested person may file written
comments with the committee within 15
days after the meeting by forwarding the
statement to the Contact Person listed on this
notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.genome.gov/council, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: December 27, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–28447 Filed 12–29–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental and
Craniofacial Research; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory Dental
and Craniofacial Research Council.
The meeting will be held as a virtual
meeting and is open to the public.
Individuals who plan to view the virtual
meeting and need special assistance or
other reasonable accommodations to
view the meeting, should notify the
Contact Person listed below in advance
of the meeting. The open session will be
videocast and can be accessed from the
NIH Videocasting and Podcasting
website (https://videocast.nih.gov/).
E:\FR\FM\30DEN1.SGM
30DEN1
80556
Federal Register / Vol. 87, No. 250 / Friday, December 30, 2022 / Notices
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Dental and Craniofacial Research Council.
Date: January 25, 2023.
Open: 10:00 a.m. to 2:00 p.m.
Agenda: Report of the Director, NIDCR and
concept clearances.
Place: National Institute of Dental and
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Closed: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Dental and
Craniofacial Research, 6701 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Lynn M. King, Ph.D.,
Executive Secretary, Division of Extramural
Activities, National Institute of Dental and
Craniofacial Research, 6701 Democracy
Blvd., Room 960, Bethesda, MD 20892–4878,
(301) 594–5006, Lynn.King@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program No. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: December 27, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–28448 Filed 12–29–22; 8:45 am]
BILLING CODE 4140–01–P
khammond on DSKJM1Z7X2PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Natural Killer
Cell Therapies for Cancer
AGENCY:
National Institutes of Health,
HHS.
VerDate Sep<11>2014
17:08 Dec 29, 2022
Jkt 259001
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to Replay Holdings
LLC (‘‘Replay’’) located in San Diego,
California.
SUMMARY:
Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before January 17, 2023 will be
considered.
DATES:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Suna Gulay French,
Technology Transfer Manager,
Telephone: (240) 276–7424; Email:
suna.gulay@nih.gov.
SUPPLEMENTARY INFORMATION:
ADDRESSES:
Intellectual Property
Group A
1. United States Provisional Patent
Application No. 62/084,654 filed
November 26, 2014, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–0–US–01];
2. PCT Patent Application No. PCT/
US2015/062269 filed November 24,
2015, entitled ‘‘Anti-Mutated KRAS T
Cell Receptors’’ [HHS Reference No. E–
028–2015–1–PCT–01];
3. Australian Patent No. 2015353720
issued June 11, 2020, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–AU–02];
4. Canadian Patent Application No.
2,968,399 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–CA–03];
5. Chinese Patent No.
ZL201580070673.7 issued November 16,
2021, entitled ‘‘Anti-Mutated KRAS T
Cell Receptors’’ [HHS Reference No. E–
028–2015–1–CN–04];
6. European Patent No. 3223850
issued January 8, 2020, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–EP–05];
a. Validated in the following
jurisdictions: AT, BE, CH, CZ, DE, ES,
FR, GB, GR, IE, IT, NL, NO, PL, PT, SE,
SI, SK, TR;
7. Israeli Patent No. 252258 issued
March 2, 2022, entitled ‘‘Anti-Mutated
KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–IL–06];
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
8. Japanese Patent No. 6863893 issued
April 5, 2021, entitled ‘‘Anti-Mutated
KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–JP–07];
9. Korean Patent Application No.
2017–7017289 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–KR–08];
10. Mexican Patent No. 384919 issued
July 29, 2021, entitled ‘‘Anti-Mutated
KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–MX–09];
11. New Zealand Patent Application
No. 732045 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–NZ–10];
12. Saudi Arabian Patent No. 7697
issued March 11, 2021, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–SA–11];
13. Singapore Patent Application No.
11201704155U effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–SG–12];
14. United States Patent No.
11,207,394 issued December 28, 2021,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–US–13];
15. Hong Kong Patent No. 1243642
issued January 22, 2021, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–HK–14];
16. European Patent Application No.
20150279.6 filed January 3, 2020,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–EP–15];
17. Singapore Patent Application No.
10201913978R filed December 31, 2019,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–SG–16];
18. Australian Patent Application No.
2020203465 filed May 26, 2020, entitled
‘‘Anti-Mutated KRAS T Cell Receptors’’
[HHS Reference No. E–028–2015–1–
AU–36];
19. Saudi Arabian Patent Application
No. 520420365 filed October 15, 2020,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–SA–37];
20. Hong Kong Patent Application No.
42020021375.9 effective filing date of
November 24, 2015, entitled ‘‘AntiMutated KRAS T Cell Receptors’’ [HHS
Reference No. E–028–2015–1–HK–38];
21. Japanese Patent Application No.
2021–063092 filed April 1, 2021,
entitled ‘‘Anti-Mutated KRAS T Cell
Receptors’’ [HHS Reference No. E–028–
2015–1–JP–40];
22. Chinese Patent Application No.
202111263859.8 filed October 27, 2021,
entitled ‘‘Anti-Mutated KRAS T Cell
E:\FR\FM\30DEN1.SGM
30DEN1
]]>Agencies
[Federal Register Volume 87, Number 250 (Friday, December 30, 2022)]
[Notices]
[Pages 80555-80556]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-28448]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Dental and Craniofacial Research; Notice of
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Dental and Craniofacial Research Council.
The meeting will be held as a virtual meeting and is open to the
public. Individuals who plan to view the virtual meeting and need
special assistance or other reasonable accommodations to view the
meeting, should notify the Contact Person listed below in advance of
the meeting. The open session will be videocast and can be accessed
from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
[[Page 80556]]
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Dental and Craniofacial
Research Council.
Date: January 25, 2023.
Open: 10:00 a.m. to 2:00 p.m.
Agenda: Report of the Director, NIDCR and concept clearances.
Place: National Institute of Dental and Craniofacial Research,
6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Closed: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Dental and Craniofacial Research,
6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lynn M. King, Ph.D., Executive Secretary,
Division of Extramural Activities, National Institute of Dental and
Craniofacial Research, 6701 Democracy Blvd., Room 960, Bethesda, MD
20892-4878, (301) 594-5006, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.nidcr.nih.gov/about, where an agenda and any
additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program No. 93.121, Oral
Diseases and Disorders Research, National Institutes of Health, HHS)
Dated: December 27, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-28448 Filed 12-29-22; 8:45 am]
BILLING CODE 4140-01-P
